| # | Title | Journal | Year | Citations |
|---|
| 1 | Current status of PET imaging in neuro-oncology | Neuro-Oncology Advances | 2019 | 78 |
| 2 | Integrated models incorporating radiologic and radiomic features predict meningioma grade, local failure, and overall survival | Neuro-Oncology Advances | 2019 | 64 |
| 3 | Treatment and surgical factors associated with longer-term glioblastoma survival: a National Cancer Database study | Neuro-Oncology Advances | 2020 | 62 |
| 4 | Radiation-induced brain injury: current concepts and therapeutic strategies targeting neuroinflammation | Neuro-Oncology Advances | 2020 | 60 |
| 5 | Mouse models of glioblastoma for the evaluation of novel therapeutic strategies | Neuro-Oncology Advances | 2021 | 47 |
| 6 | Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes | Neuro-Oncology Advances | 2020 | 43 |
| 7 | Epidemiology of synchronous brain metastases | Neuro-Oncology Advances | 2020 | 42 |
| 8 | Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study | Neuro-Oncology Advances | 2021 | 42 |
| 9 | Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives | Neuro-Oncology Advances | 2020 | 41 |
| 10 | An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival | Neuro-Oncology Advances | 2019 | 40 |
| 11 | Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults | Neuro-Oncology Advances | 2020 | 35 |
| 12 | The inflammatory microenvironment in vestibular schwannoma | Neuro-Oncology Advances | 2020 | 35 |
| 13 | Tumor-associated macrophage infiltration in meningioma | Neuro-Oncology Advances | 2019 | 34 |
| 14 | Genetics of human malignant peripheral nerve sheath tumors | Neuro-Oncology Advances | 2020 | 34 |
| 15 | Multidisciplinary patient-centered management of brain metastases and future directions | Neuro-Oncology Advances | 2020 | 30 |
| 16 | Glioblastoma as an age-related neurological disorder in adults | Neuro-Oncology Advances | 2021 | 30 |
| 17 | Therapeutic enhancement of blood–brain and blood–tumor barriers permeability by laser interstitial thermal therapy | Neuro-Oncology Advances | 2020 | 29 |
| 18 | Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis | Neuro-Oncology Advances | 2020 | 29 |
| 19 | Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study | Neuro-Oncology Advances | 2021 | 28 |
| 20 | Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults | Neuro-Oncology Advances | 2021 | 28 |
| 21 | Rapid intraoperative molecular genetic classification of gliomas using Raman spectroscopy | Neuro-Oncology Advances | 2019 | 27 |
| 22 | T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology | Neuro-Oncology Advances | 2020 | 27 |
| 23 | Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma | Neuro-Oncology Advances | 2020 | 27 |
| 24 | Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients | Neuro-Oncology Advances | 2021 | 27 |
| 25 | Laser interstitial thermal therapy | Neuro-Oncology Advances | 2020 | 26 |
| 26 | Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects | Neuro-Oncology Advances | 2020 | 26 |
| 27 | A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3 | Neuro-Oncology Advances | 2021 | 26 |
| 28 | A novel fully automated MRI-based deep-learning method for classification of 1p/19q co-deletion status in brain gliomas | Neuro-Oncology Advances | 2020 | 25 |
| 29 | Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis | Neuro-Oncology Advances | 2020 | 24 |
| 30 | Primary CNS lymphoma commonly expresses immune response biomarkers | Neuro-Oncology Advances | 2020 | 24 |
| 31 | Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter? | Neuro-Oncology Advances | 2021 | 24 |
| 32 | Constitutional mismatch repair deficiency–associated brain tumors: report from the European C4CMMRD consortium | Neuro-Oncology Advances | 2019 | 23 |
| 33 | Brain tumors in neurofibromatosis type 1 | Neuro-Oncology Advances | 2020 | 23 |
| 34 | Intraoperative DNA methylation classification of brain tumors impacts neurosurgical strategy | Neuro-Oncology Advances | 2021 | 23 |
| 35 | Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks | Neuro-Oncology Advances | 2019 | 22 |
| 36 | TERT, a promoter of CNS malignancies | Neuro-Oncology Advances | 2020 | 22 |
| 37 | Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy | Neuro-Oncology Advances | 2020 | 22 |
| 38 | Single-cell image analysis reveals a protective role for microglia in glioblastoma | Neuro-Oncology Advances | 2021 | 22 |
| 39 | Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma | Neuro-Oncology Advances | 2022 | 22 |
| 40 | Tumor microenvironment in glioblastoma: Current and emerging concepts | Neuro-Oncology Advances | 2023 | 22 |
| 41 | GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory | Neuro-Oncology Advances | 2019 | 21 |
| 42 | OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma | Neuro-Oncology Advances | 2020 | 21 |
| 43 | The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling | Neuro-Oncology Advances | 2021 | 21 |
| 44 | Metabolism-based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential | Neuro-Oncology Advances | 2020 | 20 |
| 45 | Current usage of tumor treating fields for glioblastoma | Neuro-Oncology Advances | 2020 | 20 |
| 46 | TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors | Neuro-Oncology Advances | 2020 | 20 |
| 47 | [68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas | Neuro-Oncology Advances | 2021 | 20 |
| 48 | Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply? | Neuro-Oncology Advances | 2021 | 20 |
| 49 | Introduction to radiomics and radiogenomics in neuro-oncology: implications and challenges | Neuro-Oncology Advances | 2020 | 20 |
| 50 | MRI image analysis methods and applications: an algorithmic perspective using brain tumors as an exemplar | Neuro-Oncology Advances | 2020 | 19 |
